RetinaCME
ARTICLECME

Clinical Impact of Protocol T: 2-year Data

Author(s)/Faculty: Rishi P. Singh, MD; Felipe Ferreira Conti, MD; Grace J. Tsai, BA
Release Date: 3/29/2017Expiration Date: 3/28/2018
Credit Type: CMENumber of Credits: 0.25
Content Type: ArticleProvider: Vindico Medical Education
Intravitreal pharmaceuticals have become the mainstay for retinal therapy. This activity will review the comparative efficacy and safety data from the Diabetic Retinopathy Clinical Research Network (DRCR.net) randomized clinical trial, Protocol T, which evaluated intravitreous aflibercept, bevacizumab, and ranibizumab for the treatment of diabetic macular edema.